Compare Equinix Inc (EQIX) vs Nuvalent Inc (NUVL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Equinix Inc vs Nuvalent Inc — how do they compare? Equinix Inc trades at $1,008.8 (market cap $100.85B), while Nuvalent Inc trades at $123.96 (market cap $9.81B). The key difference: Equinix Inc is far larger — about 10.3× Nuvalent Inc's market cap, and Equinix Inc pays a 1.93% dividend while Nuvalent Inc pays none. Which is the better fit depends on your goals.
| EQIX | NUVL | |
|---|---|---|
Market Cap | $100.85B | $9.81B |
Sector | Real Estate | Technology |
52-Week High | $1.12K | $123.96 |
52-Week Low | $726.09 | $72.16 |
Enterprise Value | $121.14B | $8.52B |
Dividend Yield | 1.93% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Equinix (EQIX) trades at $1,016.33, down 0.7% on the day, with a bearish technical signal despite strong analyst support. The company reported 2025 revenue of $9.22B and net income of $1.35B, with profitability improving but recent quarterly EPS misses. Cash flow trends show aggressive capital expenditure with negative net cash flow in 2025. The stock benefits from AI infrastructure partnerships and a 74.5% analyst buy rating.
Outlook remains positive due to AI-driven demand and global data center expansion, but high valuation multiples and rising debt levels pose risks. The consensus price target of $1,110 suggests upside potential, though technical indicators signal near-term caution. Key catalysts include Q2 2026 earnings and execution on growth investments.
Nuvalent (NUVL) trades at $123.96, unchanged on the day, amid a pending $124 per share acquisition by GSK. The stock shows a bullish technical signal with moving averages supporting upside, though RSI levels suggest overbought conditions. Fundamentally, the company remains unprofitable with negative ROE and ROA, while cash flow is sustained by financing activities. Recent news is dominated by merger investigations and strategic rationale for the GSK deal.
The investment outlook hinges on the acquisition closing at $124, offering limited upside from current levels. Risks include shareholder litigation and regulatory scrutiny, but the deal provides a clear exit amid ongoing losses. Analyst sentiment is mixed with a slight hold bias, reflecting uncertainty around deal completion and fairness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Equinix Inc
Equinix is a retail provider of data centers, enabling hundreds of enterprise tenants to house their servers and networking equipment in a collocated environment. Tenants can then connect with each other, through cloud service providers and telecom networks. Equinix operates 240 data centers in 66 markets worldwide and owns just less than half of them. The firm has roughly 10,000 customers, including 2,000 networks, that are dispersed over five verticals: Cloud and IT Services, Content Providers, Network and Mobile Services, Financial Services, and Enterprise. About 70% of Equinix's revenue comes from renting space to tenants and related services, and more than 15% comes from connecting customers with each other. Equinix operates as a real estate investment trust.
Read more on EQIX →About Nuvalent Inc
Nuvalent, Inc. is a clinical-stage oncology company focused on creating precisely targeted therapies for patients with cancers driven by specific gene mutations. The company leverages a deep understanding of structural biology and medicinal chemistry to design novel small-molecule kinase inhibitors to overcome resistance mechanisms in advanced solid tumors. Nuvalent is committed to developing its pipeline of candidates to address high unmet needs in the treatment of various cancers.
Read more on NUVL →
